Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas

NCT00704080 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00704080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00704080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2008
Completion date
February 28, 2013
Enrollment
54 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, malignant gliomas, mixed gliomas